Tumor Growth Rate as a Predictive Marker for Recurrence and Survival After Liver Resection in Patients with Liver Metastases of Uveal Melanoma
Toulsie Ramtohul(Université Paris Sciences et Lettres), Pascale Mariani(Université Paris Sciences et Lettres), Vincent Servois(Université Paris Sciences et Lettres), Toufik Bouhadiba(Institut Curie), Khadija Aït Raïs(Institut Curie), Sophie Gardrat(Institut Curie), Manuel Rodrigues(Inserm), Mohamed Abdul-Baki(Université Paris Sciences et Lettres), Gaëlle Pierron(Institut Curie), Nathalie Cassoux(Institut Curie)
Cited by 7
Related Papers
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial
|The Lancet Oncology|2021|812
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2021|412
SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas
|Nature Genetics|2015|375
Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)
|Journal of Clinical Oncology|2018|274